CA3292080A1 - Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer - Google Patents

Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Info

Publication number
CA3292080A1
CA3292080A1 CA3292080A CA3292080A CA3292080A1 CA 3292080 A1 CA3292080 A1 CA 3292080A1 CA 3292080 A CA3292080 A CA 3292080A CA 3292080 A CA3292080 A CA 3292080A CA 3292080 A1 CA3292080 A1 CA 3292080A1
Authority
CA
Canada
Prior art keywords
milciclib
formulations
cancer
treatment
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3292080A
Other languages
English (en)
Inventor
Kunwar Shailubhai
Original Assignee
Tiziana Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiziana Life Sciences Ltd filed Critical Tiziana Life Sciences Ltd
Publication of CA3292080A1 publication Critical patent/CA3292080A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CA3292080A 2017-11-06 2018-11-06 Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer Pending CA3292080A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582288P 2017-11-06 2017-11-06
US62/582,288 2017-11-06
CA3076023A CA3076023C (en) 2017-11-06 2018-11-06 Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3076023A Division CA3076023C (en) 2017-11-06 2018-11-06 Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3292080A1 true CA3292080A1 (en) 2026-03-02

Family

ID=64362773

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3292080A Pending CA3292080A1 (en) 2017-11-06 2018-11-06 Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
CA3076023A Active CA3076023C (en) 2017-11-06 2018-11-06 Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3076023A Active CA3076023C (en) 2017-11-06 2018-11-06 Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Country Status (5)

Country Link
US (3) US10758541B2 (https=)
EP (1) EP3706869A1 (https=)
JP (3) JP7111811B2 (https=)
CA (2) CA3292080A1 (https=)
WO (1) WO2019090332A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178239A1 (en) * 2018-03-13 2019-09-19 Board Of Regents, The University Of Texas System Methods for treatment of cancers with egfr activating mutations
JP7642556B2 (ja) * 2019-11-18 2025-03-10 中外製薬株式会社 併用医薬
CN110693839B (zh) * 2019-11-19 2022-03-08 乐普药业股份有限公司 一种甲磺酸仑伐替尼固体分散体及其制备方法和用途
CN112218626B (zh) * 2019-12-31 2023-03-24 广州帝奇医药技术有限公司 一种持续释放组合物及其制备方法
JP2021167301A (ja) * 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN112546048B (zh) * 2021-01-06 2022-11-29 天津科技大学 HKL-5-61与Osimertinib的药物组合及其应用
KR102597832B1 (ko) * 2021-01-19 2023-11-02 인천대학교 산학협력단 소라페닙의 항암효과 증진용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
BRPI0707580A2 (pt) * 2006-02-10 2011-05-10 Nerviano Medical Sciences Srl combinaÇÕes compreendendo um inibidor cdk e um anticorpo do fator de crescimento ou antimitàtico
EP2320903B1 (en) * 2008-07-29 2017-01-18 Nerviano Medical Sciences S.r.l. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
WO2016015605A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies

Also Published As

Publication number Publication date
JP2024128026A (ja) 2024-09-20
US20190134044A1 (en) 2019-05-09
JP2021509395A (ja) 2021-03-25
JP7111811B2 (ja) 2022-08-02
CA3076023C (en) 2026-04-07
JP2022136148A (ja) 2022-09-15
US20200390769A1 (en) 2020-12-17
WO2019090332A1 (en) 2019-05-09
EP3706869A1 (en) 2020-09-16
US10758541B2 (en) 2020-09-01
US20240285632A1 (en) 2024-08-29
CA3076023A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
CA3292080A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
EP3250609A4 (en) Il13ra alpha 2 binding agents and use thereof in cancer treatment
SMT202000305T1 (it) Composizioni per l'uso in metodi per il trattamento di ferite, disturbi e malattie della pelle
EP4066837A4 (en) USE OF BI853520 IN THE TREATMENT OF CANCER
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
IL266198A (en) Liposomal formulation for use in cancer treatment
IL281495A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
EP3266865A4 (en) Cell therapeutic agent for cancer treatment and combination therapy with same
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
EP3694391B8 (en) Device for use in the treatment of hemorrhoids
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
EP3668533A4 (en) PROTECTION OF NORMAL TISSUES IN THE TREATMENT OF CANCER
HK40031514A (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
EP3458031A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF CELECOXIB AND THEIR USE IN THE TREATMENT OF CELCOXIB-SENSITIVE DISEASES AND CONDITIONS
HK40064163A (en) Oligo-benzamide analogs and their use in cancer treatment
HK40020424A (en) Sulfinylpyridines and their use in the treatment of cancer
HK40056387A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
EP3209676A4 (en) Cancer and skin lesion treatment
HK40063146A (en) Novel compounds and their use in therapy
HK40021223A (en) Bicyclic compounds and their use in the treatment of cancer
HK40018432A (en) Usl-311 for use in the treatment of cancer
HK40061060A (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
HK40020423A (en) Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20251112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20251212

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251212

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251212

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20251218

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260212

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260302

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260303

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260303

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260303

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260303

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260303

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260303